Matthew L. Kaplan has bought NVCT on 2 days since May 2022
Director at Nuvectis Pharma, Inc.
SEC CIK 0001895952 · Filings on SEC.gov ↗
$115KBought
$0Sold
Nov 6Last buy
Matthew L. Kaplan's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
2 filings since May 2022, newest first
Filings come from SEC EDGAR. Not investment advice.